Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme (Q46523679)
Jump to navigation
Jump to search
scientific article published in January 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme |
scientific article published in January 2005 |
Statements
1 reference
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme (English)
1 reference
M Wirth
1 reference
C Tyrrell
1 reference
K Delaere
1 reference
M Sánchez-Chapado
1 reference
J Ramon
1 reference
D M A Wallace
1 reference
J Hetherington
1 reference
F Pina
1 reference
C Heyns
1 reference
T Borchers
1 reference
T Morris
1 reference
J Armstrong
1 reference
'Casodex' Early Prostate Cancer Trialists' Group
1 reference
1 January 2005
1 reference
8
1 reference
2
1 reference
194-200
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference